These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Han SH; Choi SH; Cho BJ; Lee Y; Lim S; Park YJ; Moon MK; Lee HK; Kang SW; Han DS; Kim YB; Jang HC; Park KS Metabolism; 2010 Nov; 59(11):1656-62. PubMed ID: 20423749 [TBL] [Abstract][Full Text] [Related]
46. Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor. de Jong KP; Hoedemakers RM; Fidler V; Bijzet J; Limburg PC; Peeters PM; de Vries EG; Slooff MJ Scand J Gastroenterol; 2004 Nov; 39(11):1141-8. PubMed ID: 15545174 [TBL] [Abstract][Full Text] [Related]
47. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Pawlak K; Ulazka B; Mysliwiec M; Pawlak D Transl Res; 2012 Nov; 160(5):346-54. PubMed ID: 22683425 [TBL] [Abstract][Full Text] [Related]
48. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients. Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040 [TBL] [Abstract][Full Text] [Related]
49. Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity. Can U; Buyukinan M; Yerlikaya FH Indian J Med Res; 2017 Mar; 145(3):327-333. PubMed ID: 28749394 [TBL] [Abstract][Full Text] [Related]
50. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140 [TBL] [Abstract][Full Text] [Related]
51. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959 [TBL] [Abstract][Full Text] [Related]
52. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Pawlak K; Mysliwiec M; Pawlak D Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089 [TBL] [Abstract][Full Text] [Related]
53. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228 [TBL] [Abstract][Full Text] [Related]
54. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317 [TBL] [Abstract][Full Text] [Related]
55. Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis. Helal I; Zerelli L; Krid M; ElYounsi F; Ben Maiz H; Zouari B; Adelmoula J; Kheder A Saudi J Kidney Dis Transpl; 2012 May; 23(3):477-83. PubMed ID: 22569431 [TBL] [Abstract][Full Text] [Related]
56. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653 [TBL] [Abstract][Full Text] [Related]
57. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease. Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634 [TBL] [Abstract][Full Text] [Related]
58. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease]. Peng Q; Wu Q; Chen CH; Hong H; Zhang LY Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593 [TBL] [Abstract][Full Text] [Related]
59. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine. Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136 [TBL] [Abstract][Full Text] [Related]
60. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]